Basel, Switzerland
ARTIDIS, founded in 2018, is a Switzerland-based clinical stage health technology company carving out a niche in the rapidly evolving field of nanotechnology for medical applications. With their pioneering approach, ARTIDIS seeks to revolutionize tissue analysis and therapy optimization by developing the first nanotechnology platform tailored for rapid diagnostics, positioning itself as a leader in precision cancer care.
Their cutting-edge platform combines nanotechnology with a holistic data solution to expedite processes in drug discovery, tissue engineering, and personalized treatment. This focus, particularly on solid tumors, aims to significantly improve patient outcomes during treatments such as chemotherapy, immunotherapy, and cell therapies.
In May 2023, ARTIDIS secured a Fr.24.60M Series A investment, underscoring investor confidence in their innovative approach and potential for impacting cancer therapies. As they continue their clinical stage efforts, ARTIDIS is well-positioned to become a pivotal player in the transformation of cancer treatment paradigms.
